stella
beta
A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC — Stella
Recruiting
Back to Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC) trials
Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations
(1 site)
China
Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai Municipality
View full record on ClinicalTrials.gov